| Abstract | We describe a 60-year-old woman with active rheumatoid arthritis (RA) and endstage renal disease secondary to hypertensive nephrosclerosis undergoing hemodialysis. She had tried multiple antirheumatic medications; however, their usefulness was limited due to toxic side effects or lack of efficacy. She was then treated with chimeric antitumor necrosis factor monoclonal antibody (infliximab), which resulted in immediate improvement in clinical and laboratory measures. After about 2 years of therapy, no side effects have been observed. This report expands the spectrum of infliximab to include RA patients with renal insufficiency. |
| Authors | Ranju Singh, Raquel Cuchacovich, Wenqun Huang, Luis R Espinoza
(Affiliation: Department of Medicine, Louisiana State University Health Science Center at New Orleans, 70112-2822, USA.)
|
| Journal | The Journal of rheumatology
(J Rheumatol)
Vol. 29
Issue 3
Pg. 636-7
(Mar 2002)
ISSN: 0315-162X Canada |
| PMID | 11908584
(Publication Type: Case Reports, Journal Article)
|
| Chemical References |
- Antibodies, Monoclonal
- Antirheumatic Agents
- infliximab
|
| Topics |
- Antibodies, Monoclonal
(administration & dosage)
- Antirheumatic Agents
(administration & dosage)
- Arthritis, Rheumatoid
(complications, therapy)
- Female
- Humans
- Kidney Failure, Chronic
(complications, therapy)
- Middle Aged
- Renal Dialysis
|
